Medicinal Products

166. Deputy Aindrias Moynihan asked the Minister for Health the up-to-date position on a medication (details supplied) to be made available through the drugs payment scheme; and if she will make a statement on the matter. [10121/25]

162. Deputy David Cullinane asked the Minister for Health to provide an update on the funded HRT scheme announced in Budget 2025; what discussions her officials have had with the Irish Pharmacy Union in relation to the scheme; and if she will make a statement on the matter. [9853/25]

163. Deputy David Cullinane asked the Minister for Health if she will provide an update on whether injectable semaglutide medicines will be made available to obesity patients on the drugs payment scheme before the end of the year; and if she will make a statement on the matter. [9854/25]

164. Deputy David Cullinane asked the Minister for Health if she is aware of the ongoing shortage of prescription packs (60 tablets) of soluble Solpadine, not to be confused with the over-the-counter packs available without prescription available in 12 and 24 tablets; if officials from her Department have discussed the shortage with the HPRA or manufacturer; and if she will make a statement on the…

165. Deputy David Cullinane asked the Minister for Health to provide an update on the timeline for the introduction of pharmacist prescribing; what recommendations from the expert taskforce have been achieved so far; and if she will make a statement on the matter. [9857/25]

185. Deputy Colm Burke asked the Minister for Health if she will consider reducing the threshold of the drugs payment scheme to €72 per month, as per the 2017 Sláintecare report; and if she will make a statement on the matter. [9954/25]

194. Deputy Ryan O'Meara asked the Minister for Health for an update on the rollout of the hormone replacement therapy programme, with specific regard to the ongoing discussions regarding dispensing fees; and if she will make a statement on the matter. [10023/25]

707. Deputy James Geoghegan asked the Minister for Health if the 34 new whole-time equivalent positions for the agencies involved in the HSE’s medicines pricing and reimbursement system, as initially prescribed in February 2023, have now been successfully filled; whether they have commenced their engagement; and if she will make a statement on the matter. [9516/25]

713. Deputy Catherine Connolly asked the Minister for Health further to Parliamentary Question No. 1086 of 5 February 2024, when hormone replacement therapy will be freely available to those with a prescription; and if she will make a statement on the matter. [9540/25]

754. Deputy Peter 'Chap' Cleere asked the Minister for Health the reason buscopan RX has been removed from the general medical scheme/medical card scheme; and if she will make a statement on the matter. [9647/25]

778. Deputy Mary Lou McDonald asked the Minister for Health if she intends to review the terms of the drugs payment scheme; if she will extend the long-term illness scheme in order to include rheumatoid arthritis as a long-term chronic illness; and if she will make a statement on the matter. [9782/25]

372. Deputy Mairéad Farrell asked the Minister for Health if she plans to implement a regulatory framework that limits the acquisition and administration of dermal fillers to qualified doctors and dentists; and if she will make a statement on the matter. [8682/25]

391. Deputy Ryan O'Meara asked the Minister for Health the current status of efforts to licence the drug concerta, in its liquid form; and if she will make a statement on the matter. [8755/25]

411. Deputy Catherine Connolly asked the Minister for Health the timeline for implementing the proposed changes to governance and safety regulations in the field of aesthetic medicine, with specific regard to dermal fillers; and if she will make a statement on the matter. [8877/25]

295. Deputy Pádraig Rice asked the Minister for Health if a drug (details supplied) will be made available to patients with biliary tract cancers; and if she will make a statement on the matter. [8436/25]

329. Deputy Willie O'Dea asked the Minister for Health the current status of the application for approval in Ireland for palforzia as an oral immunotherapy treatment for peanut allergy; and if she will make a statement on the matter. [8538/25]

904. Deputy Grace Boland asked the Minister for Health the status of negotiations her Department is engaged with to deliver selumetinib in a cost-effective manner; and if she will make a statement on the matter. [7627/25]

970. Deputy Robert O'Donoghue asked the Minister for Health to report on progress on any negotiations between the HSE and (details supplied) in relation to the price of the drug Selumetinib (Koselugo), an important drug for the treatment of neurofibromatosis; and if she will make a statement on the matter. [8086/25]

339. Deputy Paul McAuliffe asked the Minister for Health if the issue of the soluble solpadeine shortage has been resolved; and if she will make a statement on the matter. [6883/25]

207. Deputy Seán Crowe asked the Minister for Health if the drug vamorolone is currently being considered for approved use by the HSE. [6471/25]

209. Deputy Jen Cummins asked the Minister for Health when it is intended to provide free hormone replacement therapy; if people who have been charged will be reimbursed for this cost in January and February due to the promise that it would be implemented for free in 2025; and if she will make a statement on the matter. [6476/25]

222. Deputy Seán Crowe asked the Minister for Health if the drug givinostat is being considered for approval for use by the HSE. [6585/25]

702. Deputy Shane Moynihan asked the Minister for Health for an update on the introduction on the provision of free hormone replacement therapy. [5565/25]

727. Deputy Michael Healy-Rae asked the Minister for Health the reason a medication (details supplied) is not covered under the drugs payment scheme; and if she will make a statement on the matter. [5766/25]

788. Deputy John Lahart asked the Minister for Health if she will streamline HSE reimbursement processes and reduce administrative burdens to provide for a nationwide programme for safe and appropriate medicine disposal. [5998/25]